Dr. Adi Hoess, Affimed's CEO, commented, “Martin oversaw the development of Affimed’s ROCK® platform. We thank Martin for his many contributions to Affimed during his tenure as CSO, and wish him success in his future endeavors.”

The German clinical stage biopharmaceutical company also announced that it has terminated its phase 1 bispecific T-cell engager program. It will instead focus its research and development investments on advancing on-going and previously announced clinical trials for its innate cell engager candidates, AFM13 and AFM24.